EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPTBiotechnology
Healthcare
$2.99 +1.98%
+$0.26 today
- Market cap
- $250.69M
- Beta
- 1.75
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$3.16
52W Low $7.94High $19.11
Volume 2.75M
Average 0.95M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$240.11M
FY 2025 · Annual
Investing Cash Flow
$68.58M
FY 2025 · Annual
Financing Cash Flow
$173.65M
FY 2025 · Annual
+5.9% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.42M) | (102.25M) | (70.8M) | (130.87M) | (231.96M) |
| Depreciation & Amortization | 2.77M | 2.45M | 464K | 1.54M | 2.31M |
| Deferred Income Tax | (787K) | 0 | 83K | 90K | 279K |
| Stock-Based Compensation | 7.45M | 14.18M | 12.06M | 36.74M | 27.87M |
| Change in Working Capital | (1.74M) | (3.02M) | 58.88M | (27.77M) | (33.78M) |
| Accounts Receivables | (10.6M) | (2.66M) | 14.43M | (244K) | (10.67M) |
| Inventory | 1.35M | (760K) | (1.55M) | 1.6M | 492K |
| Accounts Payables | 8.48M | 1.2M | 1.52M | 5.73M | 4.68M |
| Other Working Capital | (959K) | (799K) | 44.48M | (34.86M) | (28.28M) |
| Other Non-Cash Items | 628K | 23.65M | 1.18M | (5.95M) | (4.83M) |
| Operating Cash Flow | (50.1M) | (65.01M) | 1.88M | (126.23M) | (240.11M) |
| Capital Expenditures | (156K) | (2.15M) | (3.48M) | (4.05M) | (3.28M) |
| Acquisitions (Net) | 0 | (558K) | (168K) | 0 | 155K |
| Purchases of Investments | (32.97M) | (139.12M) | (55.12M) | (398.3M) | (252.02M) |
| Sales of Investments | 0 | 124M | 55.28M | 177.05M | 318.9M |
| Other Investing Activities | 0 | 558K | 168K | 5.95M | 4.83M |
| Investing Cash Flow | (33.12M) | (17.27M) | (3.32M) | (219.36M) | 68.58M |
| Debt Repayment | (146K) | 2.1M | (40.51M) | (105K) | (105K) |
| Common Stock Issued | 216.83M | 395K | 226.17M | 163.31M | 175.14M |
| Common Stock Repurchased | 0 | (295K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 223K | (3.19M) | 1.41M | 813K | (1.39M) |
| Financing Cash Flow | 216.9M | (690K) | 187.07M | 164.02M | 173.65M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 133.68M | (82.96M) | 185.63M | (181.56M) | 2.12M |
| Free Cash Flow | (50.25M) | (67.16M) | (1.61M) | (130.28M) | (243.39M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$232.0M
+ D&A$2.3M
+ Stock-Based Comp$27.9M
+ Deferred Tax$279.0K
- Working Capital-$33.8M
- Other Non-Cash-$4.8M
= Operating Cash Flow-$240.1M
- Capex-$3.3M
= Free Cash Flow-$243.4M
Analysis
FY2025 free cash flow is -$243.4M. FCF conversion is 104.9% of net income. Operating cash flow was -$240.1M, with capex of -$3.3M. The largest bridge item is Working Capital at -$33.8M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Oct 7, 2026 | |
| 8-K | Current report | Sep 10, 2026 | |
| SC 13G | SC 13G filing | Sep 8, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 24, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 |
Does EYPT generate free cash flow?
EyePoint Pharmaceuticals, Inc. (EYPT) generated -$243.39M of free cash flow in fiscal 2025.
How much operating cash flow does EYPT produce?
Operating cash flow was -$240.11M, before capital expenditures of $3.28M.
Continue the stock analysis
Jump to another research area for this company.